Ironwood Pharmaceuticals, Inc. provided financial guidance for the full year 2022. For the year, the company expects total revenue of $420 million to $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 USD | -0.87% |
|
+5.57% | -40.38% |
Jul. 01 | Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Value-Defensive Index | CI |
Jul. 01 | Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to Russell 2000 Dynamic Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.38% | 1.09B | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022